C4 Therapeutics Inc (CCCC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, C4 Therapeutics Inc (CCCC) has a cash flow conversion efficiency ratio of -0.128x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.94 Million) by net assets ($234.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CCCC net asset quality index to measure how much of total assets are equity-financed.
C4 Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CCCC cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
C4 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C4 Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Farmland Partners Inc
NYSE:FPI
|
0.019x |
|
Hunan Haili Chemical Co Ltd
SHG:600731
|
0.026x |
|
Zhejiang Jianfeng Group Co Ltd
SHG:600668
|
0.022x |
|
BlueLinx Holdings Inc
NYSE:BXC
|
-0.093x |
|
Changshu Tongrun Auto
SHG:603201
|
N/A |
|
VITZROCELL Co.Ltd
KQ:082920
|
0.041x |
|
Joyware Electronics Co Ltd
SHE:300270
|
-0.015x |
|
Mirrabooka Investments Ltd
AU:MIR
|
-0.001x |
Annual Cash Flow Conversion Efficiency for C4 Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of C4 Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see C4 Therapeutics Inc (CCCC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $256.59 Million | $-98.69 Million | -0.385x | -27.50% |
| 2024-12-31 | $215.99 Million | $-65.16 Million | -0.302x | +30.51% |
| 2023-12-31 | $246.11 Million | $-106.84 Million | -0.434x | -18.52% |
| 2022-12-31 | $289.23 Million | $-105.94 Million | -0.366x | -64.09% |
| 2021-12-31 | $389.61 Million | $-86.97 Million | -0.223x | +6.80% |
| 2020-12-31 | $280.79 Million | $-67.25 Million | -0.239x | +51.78% |
| 2019-12-31 | $-111.96 Million | $55.61 Million | -0.497x | -333.28% |
| 2018-12-31 | $-79.75 Million | $-16.98 Million | 0.213x | -- |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more